Venture Life Group PLC Notice of analyst & investor results briefings
March 05 2018 - 2:00AM
RNS Non-Regulatory
TIDMVLG
Venture Life Group PLC
05 March 2018
5 March 2018
Venture Life Group plc
("Venture Life" or the "Group")
Notice of Results
Analyst & investor briefings
Venture Life Group plc (AIM: VLG), the international consumer
healthcare group focused on developing, manufacturing and
commercialising products for the self-care market, announces that
it will release its final results for the year ended 31 December
2017 on 22 March 2018.
Analyst briefing
A briefing for analysts will take place at the offices of
Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Thursday,
22 March 2018.
Investor briefing
A presentation to private investors will take place at Copper
Bar, Balls Brothers, 6 Adams Court, Old Broad Street, London EC2N
1DX on Monday, 26 March 2018 from 4.30pm for a 4.45pm start and
will be followed by drinks.
If you would like to register to attend either briefing, or
require further information, please contact Walbrook PR on 020 7933
8780 or email venturelife@walbrookpr.com.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive
Officer
Adrian Crockett, Chief Financial
Officer
Walbrook PR venturelife@walbrookpr.com
or +44 (0) 20 7933 8780
+44 (0) 7980 541
Paul McManus 893
+44 (0) 7876 741
Anna Dunphy 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising self-care
products globally. The Group's product range and pipeline currently
includes the UltraDEX oral care products range, food supplements
for lowering cholesterol and maintaining brain function,
dermo-cosmetics for addressing the signs of ageing, and medical
devices for improving minor aches and pains, dry eyes and itchy
skin.
The products, which typically are recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business, Biokosmes,
the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFERVTIFIIT
(END) Dow Jones Newswires
March 05, 2018 02:00 ET (07:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2023 to Apr 2024